The General Hospital Corporation

Other

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Massachusetts General Hospital Corporation

Viacell, Inc.

Joel F Habener

Melissa K Thomas

Elizabeth J Abraham

Mario Vallejo

Henryk Zulewski

Denise L Faustman

Tatsuya Yano

Svetlana Mojsov

Eva Tomas-Falco

Eva Tomas Falco

James P Hoeffler

Christopher P Miller

Nigel H Greig

Harold W Holloway

Douglas I Buckley

Andreas Lechner

Josephine M Egan

Doris Stoffers

Antonino Passaniti

Constanze Banz

Riccardo Perfetti

Doris A Stoffers

Joanne B Mallory

Colin A Leech

Anna Louise Nolan

Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, LVKGRamide, derived from the C-terminus of Glucagon-Like Peptide 1 (GLP-1).

Methods of treatment using a pentapeptide derived from the C-Terminus of Glucagon-Like Peptide 1 (GLP-1)

C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP 1), and methods of use thereof, e.g., for the treatment of obesity and obesity-related disorders, e.g., diabetes and the metabolic syndrome.

C-terminal fragments of glucagon-like peptide-1 (GLP-1)

Methods for treating fatty liver disease, e.g., hepatic steatosis, using peptide fragments of the C-terminal end of glucagon-like peptide-1 (GLP-1), e.g., GLP-1(28-36).

Methods for treating steatotic disease

Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.

Stem cells of the islets of langerhans and their use in treating diabetes mellitus

The present invention is directed to the use of Bridge-1 polynucleotides and Bridge-1 polypeptides, as well as activators and inhibitors of Bridge-1 activity, in the treatment of Bridge-1 mediated disorders, including diabetes.

Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes

The invention features a method of treating deficiency of insulin in a patient, comprising administering to a patient in need thereof hedgehog protein or nucleic acid in an amount effective to raise the level of insulin in the patient.

Methods to stimulate insulin production by pancreatic &#x3b2;-cells

Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.

Stem cells of the islets of Langerhans and their use in treating diabetes mellitus

Derivatives of glucagon-like peptide I (GLP-1) and especially GLP-1 (7-37) have been found to have insulinotropic activity. The invention pertains to a composition comprising an acid addition salt of GLP-I (7-37) and to a composition comprising a carboxylate salt of GLP-I (7-37). The invention also pertains to method of treating type II diabetes mellitus by providing derivatives of GLP-I (7-37) to the patient.

Insulinotropic hormone derivatives and uses thereof

The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragmets thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.

Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof

Method of pre-inducing a state of immune tolerance before organ transplantation

Methods to stimulate insulin production by pancreatic beta-cells

Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell

Derivatives of glucagon-like peptide I (GLP-1) and especially GLP-1(7-36) have been found to have insulinotropic activity. The invention pertains to the use of GLP-1(7-36) for the treatment of type II diabetes mellitus.

Insulinotropic hormone and uses thereof

Methods for screening a patient for pancreatic disease are disclosed and are based upon detection of a mutation in the gene encoding insulin promoter factor-,(IPF-,) which is linked to diabetes mellitus and pancreatic agenesis.

Compositions and methods for detecting pancreatic disease

Growing community of inventors

Newton Centre, MA, United States of America

Joel F Habener